Toxicity Considerations in HR+ Breast Cancer Treatment

Opinion
Video

Virginia Kaklamani, MD, offers clinical insights on treatment toxicity considerations in HR+ breast cancer, and the Oncology Brothers outline key takeaways from the discussion.

Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Related Content
Data from the phase 3 EMBER-3 trial support the approval of imlunestrant in this breast cancer population.

FDA Approves Imlunestrant in ER+/HER2– ESR1+ Breast Cancer

Russ Conroy
September 25th 2025
Article

Data from the phase 3 EMBER-3 trial support the approval of imlunestrant in this breast cancer population.

Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

3 Things You Should Know About TROP2 as a Therapeutic Target in Triple-Negative Breast Cancer

3 Things You Should Know About TROP2 as a Therapeutic Target in Triple-Negative Breast Cancer

ONCOLOGY Staff
September 23rd 2025
Article

Read an expert-led article on the latest advancements in TROP2-targeted antibody-drug conjugates for treating triple-negative breast cancer and improving patient outcomes.

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

ProSense® is a minimally invasive treatment option that destroys tumors by freezing them, utilizing liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction.

ProSense Cryoablation Satisfies Patients With Breast Cancer vs Alternatives

Tim Cortese
September 9th 2025
Article

THERMAC trial results revealed that the ProSense® cryoablation system showed no complications, and the highest complete ablation rate in breast cancer.

Trastuzumab pamirtecan’s developers plan to discuss next steps regarding a submission of a biologics license application for this breast cancer population.

Trastuzumab Pamirtecan Improves PFS in HER2+ Metastatic Breast Cancer

Roman Fabbricatore
September 7th 2025
Article

Trastuzumab pamirtecan’s developers plan to discuss next steps regarding a submission of a biologics license application for this breast cancer population.